GLSI - Greenwich LifeSciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
0
0
0
0
0
Operating Expenses
Research Development
6,081
6,476
3,560
1,058
2,606
Selling General and Administrative
1,441
1,565
1,038
806.188
818.887
Total Operating Expenses
7,523
8,040
4,598
1,864
3,425
Operating Income or Loss
-7,523
-8,040
-4,598
-1,864
-3,425
Income Before Tax
-7,395
-7,825
-4,571
-1,863
-3,425
Income from Continuing Operations
-7,395
-7,825
-4,571
-1,863
-3,425
Net Income
-7,395
-7,825
-4,571
-1,863
-3,425
Net Income available to common shareholders
-7,395
-7,825
-4,571
-1,863
-3,425
Basic EPS
-
-
-0.35
-0.20
-0.29
Diluted EPS
-
-
-0.35
-0.20
-0.29
Basic Average Shares
-
-
12,944
9,499
11,970
Diluted Average Shares
-
-
12,944
9,499
11,970
EBITDA
-
-8,037
-4,594
-1,860
-3,422